Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations.

@article{Kohn1997PhaseIT,
  title={Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations.},
  author={Elise C. Kohn and William D. Figg and Gisele A. Sarosy and Kenneth S. Bauer and Paul Andrew Davis and Martin {\vS}oltis and A Thompkins and Lance A. Liotta and Eddie B. Reed},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1997},
  volume={15 5},
  pages={1985-93}
}
PURPOSE Cytostatic agents targeted against angiogenesis and tumor cell invasive potential form a new class of investigational drugs. Orally administered carboxyamidotriazole (CAI) (NSC609974) is both antiangiogenic and antimetastatic. An encapsulated micronized powder formulation has been developed to optimize CAI administration. A phase I dose escalation trial with pharmacokinetic analysis has been performed. PATIENTS AND METHODS Twenty-one patients with refractory solid tumors and good end… CONTINUE READING
26 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

Similar Papers

Loading similar papers…